Pegfilgrastim [Pegylated Filgrastim]

Patients With Cancer Receiving Myelosuppressive Chemotherapy: Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia

Pegfilgrastim is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Patients With Hematopoietic Subsyndrome Of Acute Radiation Syndrome: Pegfilgrastim is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation